76 related articles for article (PubMed ID: 23589178)
1. Phase I dose-escalation study of VB-111, an antiangiogenic virotherapy, in patients with advanced solid tumors.
Brenner AJ; Cohen YC; Breitbart E; Bangio L; Sarantopoulos J; Giles FJ; Borden EC; Harats D; Triozzi PL
Clin Cancer Res; 2013 Jul; 19(14):3996-4007. PubMed ID: 23589178
[TBL] [Abstract][Full Text] [Related]
2. VB-111 for cancer.
Triozzi PL; Borden EC
Expert Opin Biol Ther; 2011 Dec; 11(12):1669-76. PubMed ID: 21961496
[TBL] [Abstract][Full Text] [Related]
3. VB-111: a novel anti-vascular therapeutic for glioblastoma multiforme.
Gruslova A; Cavazos DA; Miller JR; Breitbart E; Cohen YC; Bangio L; Yakov N; Soundararajan A; Floyd JR; Brenner AJ
J Neurooncol; 2015 Sep; 124(3):365-72. PubMed ID: 26108658
[TBL] [Abstract][Full Text] [Related]
4. A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients.
Li JL; Liu HL; Zhang XR; Xu JP; Hu WK; Liang M; Chen SY; Hu F; Chu DT
Gene Ther; 2009 Mar; 16(3):376-82. PubMed ID: 19092859
[TBL] [Abstract][Full Text] [Related]
5. Biological activities of a recombinant adenovirus p53 (SCH 58500) administered by hepatic arterial infusion in a Phase 1 colorectal cancer trial.
Atencio IA; Grace M; Bordens R; Fritz M; Horowitz JA; Hutchins B; Indelicato S; Jacobs S; Kolz K; Maneval D; Musco ML; Shinoda J; Venook A; Wen S; Warren R
Cancer Gene Ther; 2006 Feb; 13(2):169-81. PubMed ID: 16082381
[TBL] [Abstract][Full Text] [Related]
6. A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer.
Small EJ; Carducci MA; Burke JM; Rodriguez R; Fong L; van Ummersen L; Yu DC; Aimi J; Ando D; Working P; Kirn D; Wilding G
Mol Ther; 2006 Jul; 14(1):107-17. PubMed ID: 16690359
[TBL] [Abstract][Full Text] [Related]
7. Intratumoral adenovirus-mediated suicide gene transfer for hepatic metastases from colorectal adenocarcinoma: results of a phase I clinical trial.
Sung MW; Yeh HC; Thung SN; Schwartz ME; Mandeli JP; Chen SH; Woo SL
Mol Ther; 2001 Sep; 4(3):182-91. PubMed ID: 11545608
[TBL] [Abstract][Full Text] [Related]
8. A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors.
Rosen LS; Senzer N; Mekhail T; Ganapathi R; Chai F; Savage RE; Waghorne C; Abbadessa G; Schwartz B; Dreicer R
Clin Cancer Res; 2011 Dec; 17(24):7754-64. PubMed ID: 21976535
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and pharmacodynamic study of intratumoral injection of an adenovirus encoding endostatin in patients with advanced tumors.
Li HL; Li S; Shao JY; Lin XB; Cao Y; Jiang WQ; Liu RY; Zhao P; Zhu XF; Zeng MS; Guan ZZ; Huang W
Gene Ther; 2008 Feb; 15(4):247-56. PubMed ID: 18097470
[TBL] [Abstract][Full Text] [Related]
10. Phase 1/2a, dose-escalation, safety, pharmacokinetic and preliminary efficacy study of intratumoral administration of BC-819 in patients with unresectable pancreatic cancer.
Hanna N; Ohana P; Konikoff FM; Leichtmann G; Hubert A; Appelbaum L; Kopelman Y; Czerniak A; Hochberg A
Cancer Gene Ther; 2012 Jun; 19(6):374-81. PubMed ID: 22498722
[TBL] [Abstract][Full Text] [Related]
11. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity.
Nemunaitis J; Cunningham C; Buchanan A; Blackburn A; Edelman G; Maples P; Netto G; Tong A; Randlev B; Olson S; Kirn D
Gene Ther; 2001 May; 8(10):746-59. PubMed ID: 11420638
[TBL] [Abstract][Full Text] [Related]
12. A phase I/II dose escalation and activity study of intravenous injections of OCaP1 for subjects with refractory osteosarcoma metastatic to lung.
Benjamin R; Helman L; Meyers P; Reaman G
Hum Gene Ther; 2001 Aug; 12(12):1591-3. PubMed ID: 11529247
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors.
Plummer R; Vidal L; Griffin M; Lesley M; de Bono J; Coulthard S; Sludden J; Siu LL; Chen EX; Oza AM; Reid GK; McLeod AR; Besterman JM; Lee C; Judson I; Calvert H; Boddy AV
Clin Cancer Res; 2009 May; 15(9):3177-83. PubMed ID: 19383817
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results.
Rugo HS; Herbst RS; Liu G; Park JW; Kies MS; Steinfeldt HM; Pithavala YK; Reich SD; Freddo JL; Wilding G
J Clin Oncol; 2005 Aug; 23(24):5474-83. PubMed ID: 16027439
[TBL] [Abstract][Full Text] [Related]
15. Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas.
Posey JA; Saif MW; Carlisle R; Goetz A; Rizzo J; Stevenson S; Rudoltz MS; Kwiatek J; Simmons P; Rowinsky EK; Takimoto CH; Tolcher AW
Clin Cancer Res; 2005 Nov; 11(21):7866-71. PubMed ID: 16278410
[TBL] [Abstract][Full Text] [Related]
16. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
Eskens FA; Steeghs N; Verweij J; Bloem JL; Christensen O; van Doorn L; Ouwerkerk J; de Jonge MJ; Nortier JW; Kraetzschmar J; Rajagopalan P; Gelderblom H
J Clin Oncol; 2009 Sep; 27(25):4169-76. PubMed ID: 19636022
[TBL] [Abstract][Full Text] [Related]
17. Phase I clinical and pharmacokinetic study of kahalalide F administered weekly as a 1-hour infusion to patients with advanced solid tumors.
Pardo B; Paz-Ares L; Tabernero J; Ciruelos E; García M; Salazar R; López A; Blanco M; Nieto A; Jimeno J; Izquierdo MA; Trigo JM
Clin Cancer Res; 2008 Feb; 14(4):1116-23. PubMed ID: 18281545
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic adenovirus ICOVIR-7 in patients with advanced and refractory solid tumors.
Nokisalmi P; Pesonen S; Escutenaire S; Särkioja M; Raki M; Cerullo V; Laasonen L; Alemany R; Rojas J; Cascallo M; Guse K; Rajecki M; Kangasniemi L; Haavisto E; Karioja-Kallio A; Hannuksela P; Oksanen M; Kanerva A; Joensuu T; Ahtiainen L; Hemminki A
Clin Cancer Res; 2010 Jun; 16(11):3035-43. PubMed ID: 20501623
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors.
Sangro B; Mazzolini G; Ruiz J; Herraiz M; Quiroga J; Herrero I; Benito A; Larrache J; Pueyo J; Subtil JC; Olagüe C; Sola J; Sádaba B; Lacasa C; Melero I; Qian C; Prieto J
J Clin Oncol; 2004 Apr; 22(8):1389-97. PubMed ID: 15084613
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II adenoviral p53 gene therapy for chemoradiation resistant advanced esophageal squamous cell carcinoma.
Shimada H; Matsubara H; Shiratori T; Shimizu T; Miyazaki S; Okazumi S; Nabeya Y; Shuto K; Hayashi H; Tanizawa T; Nakatani Y; Nakasa H; Kitada M; Ochiai T
Cancer Sci; 2006 Jun; 97(6):554-61. PubMed ID: 16734736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
